Irinotecan Hydrochloride Liposome Injection (II); Oxaliplatin; 5Fluorouracil; Calcium folinate + nab-paclitaxel; gemcitabine
Phase 3Recruiting 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
First-line Treatment of Metastatic Pancreatic Cancer
Conditions
First-line Treatment of Metastatic Pancreatic Cancer
Trial Timeline
Dec 2, 2025 → Dec 1, 2028
NCT ID
NCT07238283About Irinotecan Hydrochloride Liposome Injection (II); Oxaliplatin; 5Fluorouracil; Calcium folinate + nab-paclitaxel; gemcitabine
Irinotecan Hydrochloride Liposome Injection (II); Oxaliplatin; 5Fluorouracil; Calcium folinate + nab-paclitaxel; gemcitabine is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for First-line Treatment of Metastatic Pancreatic Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07238283. Target conditions include First-line Treatment of Metastatic Pancreatic Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07238283 | Phase 3 | Recruiting |
Competing Products
2 competing products in First-line Treatment of Metastatic Pancreatic Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate + nab-paclitaxel; gemcitabine | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| HRS-4642 + AG + HRS-4642 placebo + AG | Jiangsu Hengrui Medicine | Phase 3 | 77 |